IRWD - Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc

IRWD

Ironwood Pharmaceuticals develops and commercializes therapies for gastrointestinal and rare diseases. Its primary products include linaclotide for constipation-related conditions and investigational drugs for visceral pain and short bowel syndrome.

⚕️ Healthcare NASDAQ Listed 2010 $ USD
$1,000 invested 10 years ago →$309today

Score Overview

1 Year
Score
Net Growth440.73%
Net TrendGrew
Net Income Consistency—
Rev Growth31.46%
Rev TrendGrew
Revenue Consistency—
5 Years
Score3.0
Net Growth-75.42%
Net Trend33%
Net Income Consistency—
Rev Growth-5.91%
Rev Trend40%
Revenue Consistency—
10 Years
Score
Net Growth258.94%
Net Trend50%
Net Income Consistency
Rev Growth42.11%
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth345.12%
Net Trend50%
Net Income Consistency
Rev Growth8x
Rev Trend69%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Ironwood Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by Net Income Consistency.

Has not reached the top 50 on Net Income Consistency in any year we have ranked.

  • IRWD

2020: 89.3% · 2021: 92.5% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 3.57—
1 Year2025-10-22
$ 1.57127.39%
5 Years2021-10-22
$ 13.03-72.60%
10 Years2016-10-21
$ 11.54-69.07%
All Time2010-02-03
$ 9.75-63.39%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 389M$ 129M$ 79M
2025$ 296M$ 24M$ 215M
2024$ 351M$ 88M
2023$ 442M-$ 1.00B$ 92M
2022$ 410M$ 175M$ 656M
2021$ 413M$ 528M$ 620M
2020$ 389M$ 106M$ 364M
2019$ 428M$ 21M$ 177M
2018$ 346M-$ 282M$ 173M
2017$ 298M-$ 116M$ 221M
2016$ 273M-$ 81M$ 305M
2015$ 149M-$ 142M$ 439M
2014$ 76M-$ 189M$ 248M
2013$ 22M-$ 272M$ 197M
2012$ 150M-$ 72M$ 168M
2011$ 65M-$ 64M$ 164M
IPO2010$ 43M-$ 52M$ 248M
IRWD - Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc fundamental performance

Between 2015 and 2025, revenue grew from $ 149M to $ 296M and net income went from -$ 142M to $ 24M. Revenue increased in 6 of those 10 years; net income in 5.

Across Ironwood Pharmaceuticals Inc's full reported history, from 2010 to 2025, revenue grew from $ 43M to $ 296M and net income went from -$ 52M to $ 24M. Revenue increased in 69% of the years measured; net income in 50%.

Ironwood Pharmaceuticals Inc currently holds a 5-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.

Membership

Continue IRWD’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies